Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

Mohammad Krayem; Ahmad Najem; Fabrice Journe; Renato Morandini; François Sales; Ahmad Awada; Ghanem E. Ghanem

doi:10.18632/oncotarget.28580

Oncotarget

On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.
Learn more.

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Retraction:

Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

PDF | How to cite

Oncotarget. 2024; 15:354-354. https://doi.org/10.18632/oncotarget.28580

Metrics: PDF 154 views | ?

Mohammad Krayem¹, Ahmad Najem¹, Fabrice Journe^1,2, Renato Morandini¹, François Sales¹, Ahmad Awada³ and Ghanem E. Ghanem¹

¹Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
²Service d’Anatomie Humaine et d’Oncologie Expérimentale, Université de Mons, Mons, Belgium
³Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

Published: June 03, 2024

Copyright: © 2024 Krayem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: Multiple internal duplications of western blot images illustrating the data of different experiments have been discovered throughout Figure 3C. In addition, Figure 3C also contains blots images from Figure 2A in an earlier published paper [1]. Therefore, with the agreement of all authors, the Scientific Integrity office at Oncotarget has decided to retract this paper.

REFERENCES

1. Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Eur J Cancer. 2016; 55:98–110. https://doi.org/10.1016/j.ejca.2015.12.002. [PubMed].

Original article: Oncotarget. 2018; 9:31888–31903. DOI: https://doi.org/10.18632/oncotarget.25879

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28580

Announcements

Publication Alerts

Retraction:

Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma